Question explored with the scientific record
Did any of the Covid vaccines actually give people covid
No. The COVID-19 vaccines did not give people COVID-19. They are not made from the live virus that causes the disease.
The vaccines use a piece of genetic code (mRNA) or a harmless viral vector to teach your cells to make the spike protein, not the whole virus [10]. This spike protein alone cannot cause a COVID-19 infection. The evidence shows vaccinated people do get infected, but these are "breakthrough" infections from exposure to the actual SARS-CoV-2 virus circulating in the community, not from the shot itself [1, 2, 3, 5, 6, 7, 8, 9].
Several studies confirm that vaccinated people get infected at lower rates than unvaccinated people. A large Sicilian study found that full mRNA vaccination cut the risk of reinfection by more than half compared to being unvaccinated [5]. A study of over 3.9 million people showed Moderna's vaccine prevented infection better than Pfizer's, but both groups still had breakthrough cases [6]. The vaccines reduce the chance of catching the virus, but they do not eliminate it entirely, especially as new variants like Omicron emerged [9].
The confusion likely comes from the term "breakthrough infection." This means a vaccinated person caught the virus from someone else, not from the vaccine. The vaccines are designed to prevent severe illness and death, which they do well, but they are not a perfect shield against infection itself [3, 4, 8].
My call: The COVID-19 vaccines do not cause COVID-19. Confidence: high.
Sources used 10
-
Relationship between antibody titer than the Incidence of Infection After Complete Dose of COVID-19 Astrazeneca Vaccination Based on Sociodemographics
Sociodemographic factors—gender, age, comorbidity, smoking, and drinking—were correlated with Covid-19 infection after complete-dose AstraZeneca vaccination in a prospective convenience cohort.
DOI: 10.22270/jddt.v14i3.6462 -
Incidence Rate of Covid-19 Infection in People with Fourth Dose of Vaccines Bivalent Mrna from October 2022 to October 2023 in A General Medicine Office in Toledo (Spain)
Crude incidence of Covid-19 infection among adults with a fourth dose of bivalent mRNA vaccines in a Toledo general practice (Oct 2022–Oct 2023) was 2%, higher in those aged ≥65 years (3%) and in women (2%).
DOI: 10.31579/2639-4162/133 -
Vaccine effectiveness in symptom and viral load mitigation in COVID-19 breakthrough infections in South Korea
In a South Korean retrospective cohort of 9,030 COVID-19 patients, full vaccination was associated with reduced symptoms such as cough, sputum, and myalgia, and with lower high viral load, especially in patients under 40 years.
DOI: 10.1371/journal.pone.0290154 -
The Effectiveness Of COVID-19 Vaccination in Protecting Older Adults Against Emerging Infectious and Virulent Strains
A systematic review of 10 studies found COVID-19 vaccination protects older adults against severe disease and mortality, booster doses sustain protection, and mRNA vaccines appear more effective than inactivated vaccines.
DOI: 10.54097/9qxcpk04 -
Low Risk of SARS-CoV-2 Reinfection for Fully or Boosted mRNA Vaccinated Subjects in Sicily: A Population-Based Study Using Real-World Data
In a population-based retrospective Sicilian cohort of 905,829 adults, full and booster mRNA vaccination was associated with substantially lower SARS-CoV-2 reinfection risk than no vaccination.
DOI: 10.3390/vaccines11121757 -
Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine
In real-world U.S. data, Moderna's mRNA-1273 vaccine shows modestly better protection against SARS-CoV-2 infection than Pfizer-BioNTech's BNT162b2 over 30–90 days after full vaccination, with no significant difference in severe outcomes.
DOI: 10.1038/s41467-022-30059-3 -
Risk of SARS-CoV-2 Breakthrough Infection in Vaccinated Cancer Patients: A Retrospective Cohort Study
In 9417 vaccinated cancer patients, the breakthrough infection rate was 1.1% during the delta variant surge; 27% of breakthrough infections required hospitalization and 5% were fatal, with higher risk in hematologic malignancy, multiple myeloma, and antineoplastic therapy.
DOI: 10.1186/s13045-022-01290-8 -
Severity of SARS-CoV-2 infection among vaccinated individuals: A hospital-based study
Among 307 vaccinated patients hospitalized with COVID-19 in Sri Lanka, comorbidity was the strongest predictor of severe/critical illness, and severe disease was more frequent among Sinopharm than Covishield recipients, while fully vaccinated breakthrough cases had lower severe/…
DOI: 10.4038/cmj.v67i4.9742 -
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
This test-negative case-control study in Israel found that BNT162b2 booster vaccine effectiveness against Omicron infection waned rapidly with time since vaccination, from 35.7% at 2 months to 16% at 5 months, with no significant waning against severe disease.
DOI: 10.1038/s41467-022-30884-6 -
Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic
A narrative review arguing that dendritic cell-based vaccines oriented toward T cell immunity could provide durable and variant-resistant protection against SARS-CoV-2.
DOI: 10.3389/fimmu.2022.989685